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Abstract In contrast to conventional gene transfer strat-
egies, the direct introduction of recombinant proteins into
cells bypasses the risk of insertional mutagenesis and offers
an alternative to genetic intervention. Here, we explore
whether protein transduction of the gliogenic transcription
factor Nkx2.2 can be used to promote oligodendroglial
differentiation of mouse embryonic stem cell (ESC)-
derived neural stem cells (NSC). To that end, a recombi-
nant cell-permeant form of Nkx2.2 protein was generated.
Exposure of ESC-derived NSC to the recombinant protein
and initiation of differentiation resulted in a two-fold
increase in the number of oligodendrocytes. Furthermore,
Nkx2.2-transduced cells exhibited a more mature oligo-
dendroglial phenotype. Comparative viral gene transfer
studies showed that the biological effect of Nkx2.2 protein
transduction is comparable to that obtained by lentiviral
transduction. The results of this proof-of-concept study
depict direct intracellular delivery of transcription factors
as alternative modality to control lineage differentiation in
NSC cultures without genetic modiﬁcation.
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Introduction
Controlled differentiation into neuronal and glial lineages
is a key prerequisite for the biomedical application of
neural stem cells (NSC). In addition to exposure to
extrinsic growth and differentiation factors, expression of
instructive transcription factors has been employed to
modulate cell fate decisions. Viral transduction of the
transcription factors Nurr1 and Lmx1a has recently been
used to promote the differentiation of midbrain dopamine
neurons from mouse embryonic stem cells (ESC) [1–3]. A
central problem in most viral and non-viral gene trans-
duction systems is random integration of the vectors in the
host genome, which can result in insertional mutagenesis
potentially leading to aberrant differentiation and tumor
formation. On the other hand, direct intracellular delivery
of bioactive proteins and nucleic acids is limited by low
permeability of the eukaryotic cell membrane. Recently,
the generation of cell-permeant proteins has emerged as a
promising new avenue for intracellular protein transfer
[4–6]. Transduction is enabled by linking the protein of
interest to protein transduction domains (PTD), also des-
ignated cell-penetrating peptides (CPP). The short PTD
from the transactivator protein (TAT) of HIV-1 [7–9], the
viral protein 22 (VP22) of Herpes simplex virus [10] and
the antennapedia homeoprotein of Drosophila [11, 12] have
been fused to a variety of proteins, including cell cycle
factors [13, 14], DNA recombinases [15, 16] and tran-
scription factors [17–21]. Highly efﬁcient delivery of
biologically active proteins was reported for a wide variety
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as well as neural precursor cells and post-mitotic neurons
[24]. Although cell-permeant proteins have mainly been
shown to work in vitro, their functionality was also dem-
onstrated in vivo [25–29]. The mechanism of cellular
uptake is not fully understood but appears to involve at
least two cellular processes, endocytosis and direct mem-
brane penetration [30, 31].
There is strong evidence that the molecular control of
oligodendrocyte speciﬁcation and differentiation from
neural stem or progenitor cells is regulated by the tran-
scription factors Olig1/2, Nkx2.2, Sox9 and Sox10 [32]
(Fig. 2a). Several studies have demonstrated that expres-
sion of the basic helix-loop-helix transcription factors
Olig1 and Olig2 is required for oligodendrocyte lineage
determination in vivo [33–35]. In addition, the high-
mobility transcriptional regulator Sox10 and the homeo-
domain transcription factor Nkx2.2 have been proposed to
directly regulate oligodendrocyte differentiation and mye-
lin gene expression. Mutations of both genes result in a
decreased number of oligodendrocytes in the CNS [36, 37].
These ﬁndings suggest that Sox10 and Nkx2.2 coopera-
tively mediate the function of Olig2 to control
oligodendrocyte differentiation and maturation. Con-
versely, expression of Nkx2.2 in combination with Olig2
can induce ectopic formation of mature myelin basic pro-
tein (MBP)-positive oligodendrocytes in embryonic
chicken spinal cord [38]. Along this line, inducible
expression of Olig2 has been used to promote the genera-
tion of oligodendrocytes from murine ESC [39] and
transduction of human fetal neural precursors with an
Olig2-encoding lentivirus induces their commitment
towards an oligodendroglial fate in vitro and in vivo [40].
In human adult-derived NSC, co-transfection with Olig2
and Nkx2.2 or Sox10 and Nkx2.2 induces oligodendrocyte
differentiation and maturation [41]. Thus, overexpression
of transcription factors that play essential roles in oligo-
dendrocyte development facilitate oligodendrocyte
speciﬁcation and differentiation in neural stem and pro-
genitor cells.
In this study, we explore direct intracellular delivery of
recombinant Nkx2.2 protein as an alternative tool to
modulate and augment the differentiation of ESC-derived
NSC into oligodendrocytes without genetic modiﬁcation.
Materials and methods
Culture and differentiation of NSC
Clonally derived mouse ESC-derived NSC (line NS-5)
were cultured according to Conti et al. [42]. Oligoden-
droglial differentiation was performed as described [43].
Brieﬂy, cells were plated on polyornithin/laminin-coated
dishes and proliferated in NSC expansion medium, which
is composed of NS-A medium (Euroclone, Pero, Italy) plus
N2 supplement (Invitrogen, Karlsruhe, Germany), 10 ng/ml
ﬁbroblast growth factor 2 (FGF2; Invitrogen) and
10 ng/ml epidermal growth factor (EGF; Invitrogen). For
differentiation, this medium was replaced by DMEM/F12
(Invitrogen) supplemented with N2 (differentiation med-
ium), and the cells were propagated for 4 days without
FGF2 and EGF but in the presence of 3,3,5-tri-iodothyro-
nine (T3; 30 ng/ll; Sigma, Steinheim, Germany) and
ascorbic acid (AA; 200 lM; Sigma).
Protein expression, puriﬁcation and transduction
Recombinant Nkx2.2 fusion protein was expressed from a
pTriEx1-based plasmid in E. coli. Brieﬂy, Nkx2.2-speciﬁc
primers were used to amplify the coding sequence from
human nkx2.2 cDNA clones (Open Biosystems, Hunts-
ville, AL) by PCR reaction. The sequence was cloned
between the AvrII and NheI sites of the pSESAME-C
vector [17] to construct a fusion protein comprising the
protein transduction sequence at the C-terminus. The
fusion protein was puriﬁed from the E. coli lysates using
Ni
2? afﬁnity chromatography, eluted and concentrated in
a glycerol stock. For protein transduction the protein was
diluted in cell culture medium. For most experiments the
protein was used at a ﬁnal concentration of 5 lg/ml.
Fresh protein was added every day. NSC were treated
with protein during the last day of proliferation and
throughout the subsequent 4-day growth factor with-
drawal-induced differentiation in the presence of T3
and AA.
Labeling of recombinant protein
For tracking of transducible Nkx2.2, the protein was
labeled with N-hydroxy-succinimide-rhodamine (NHS-
rhodamine, Pierce, Rockford, IL). To that end, 2.5 ml of
the recombinant protein (200 lg/ml) were mixed with
250 ll NHS-rhodamine (37 lg/ml) and incubated for 2 h
in darkness. The labeled protein was transferred onto a
desalting column and eluted with PBS/DMEM high glu-
cose (1:1). Protein concentration was quantiﬁed by
Bradford staining (Bio-Rad, Cambridge, MA). The eluate
was used immediately or divided into aliquots and frozen
in a dry ice/ethanol bath and stored at -80C. For appli-
cation of the labeled protein on NSC, the cells were washed
twice with PBS and incubated with NSC expansion med-
ium containing the labeled protein (50 lg/ml). After
30 min the cells were washed three times with heparin
(0.5 mg/ml, Sigma) to detach protein bound to the cell
surface. Nuclei were visualized by Hoechst staining
2440 K. Stock et al.(1:1,000, Sigma) for 15 min at 37C, and the labeled
protein was tracked using ﬂuorescence microscopy.
Immunocytochemical analysis
For immunocytochemical analysis cells were ﬁxed with
4% PFA for 10 min at room temperature. After washing in
PBS, cells were blocked with 5% normal goat serum in
PBS and incubated overnight in 1% normal goat serum in
PBS with the following primary antibodies: Olig2 (rabbit
IgG; 1:3,000; Chemicon, Hofheim, Germany), Nkx2.2
(mouse IgG; 1:1,000; Thomas M. Jessell, Columbia Uni-
versity, New York), Sox10 (mouse IgG; 1:1,500; Michael
Wegner, University of Erlangen-Nu ¨rnberg, Germany),
Sox9 (rabbit IgG; 1:300; Chemicon), O4 (mouse IgM;
1:100; Chemicon), GFAP (rabbit IgG; 1:1,000; DAKO,
Hamburg, Germany), NG2 (rabbit IgG; 1:75; Chemicon),
bIII-tubulin (rabbit IgG; 1:1000; Covance, Denver, USA)
and GFP (rabbit IgG; 1:500; Acris Antibodies GmbH,
Hiddenhausen, Germany). For intracellular antigens, cells
were permeabilized in PBS containing 0.1% Triton X-100.
Antigens were visualized using appropriate ﬂuorochrome-
conjugated secondary antibodies applied for 1 h: goat anti-
mouse IgM-Cy3 (1:250, Jackson Immuno Research, West
Baltimore Pike, PA, USA), goat anti-mouse IgG-Alexa 555
(1:700, Invitrogen, Karlsruhe, Germany) and goat anti-
rabbit IgG-Alexa 488 (1:800, Invitrogen). 40-6-Diamidino-
2-phenylindole (DAPI, Sigma) was used for nuclear
counterstaining. Labeled cells were preserved in Vecta-
shield (Vector Laboratories, Burlingame, CA) and
analyzed using a Zeiss ﬂuorescence microscope. Quanti-
tative analysis was carried out by counting the number of
immunoreactive cells per total number of viable cells as
determined by DAPI staining. Data for each marker are
based on triplicate cultures with C20 randomly chosen high
power ﬁelds quantiﬁed for each staining.
Western blot analysis
For preparation of cell lysates NSC were washed twice
with ice-cold PBS. Ice-cold lysis buffer (50 mM Tris-HCl
pH = 8, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40) con-
taining protease inhibitors (2 lg/ml aprotinin, 10 lg/ml
leupeptin, 100 lg/ml phenylmethylsulphonyl ﬂuoride;
Sigma) was added, and cells were collected using a cell
scraper. The cell suspension was centrifuged (10 min,
1,800 rpm, 4C), the supernatant was discarded, and the
cell pellet was resuspended in lysis buffer. After an incu-
bation time of 15 min, the lysates were centrifuged again
(15 min, 13,000g,4 C). The protein concentration in the
supernatant was determined by Bradford analysis. From
each sample 35 lgi n2 9 SDS loading buffer was used
for immunoblot analysis. To assess the stability of the
recombinant Nkx2.2-NTH protein in culture medium,
samples were taken from the medium at different time
points. After centrifugation 40 ll of the supernatant in 29
SDS loading buffer were used for immunoblot analysis.
Extracts from the lysates or culture medium were separated
on a 12% SDS-polyacrylamide gel and electroblotted onto
nitrocellulose membranes (Amersham Bioscience, Frei-
burg, Germany). The blots were blocked with 5% fat-free
milk powder in PBS/0.05%Tween 20 and probed with
primary antibodies to Nkx2.2 (mouse IgG, 1:200; Thomas
M. Jessell, Columbia University, New York, NY) or Penta-
His horseradish peroxidase (HRP) (Cell Signaling Tech-
nology, Danvers, MA) at 4C overnight. For detection of
Nkx2.2 a HRP-conjugated secondary antibody (anti-mouse
HRP; 1:3,000; Cell Signaling, Danvers, MA) was applied
after washing for 1 h at RT. Signals were visualized with
an enhanced luminol solution (SuperSignal System, Pierce,
Rockford, IL).
Lentiviral vector construction and transduction
The lentiviral constructs are based on the commercially
available pLenti6/V5 vector (Invitrogen). The Nkx2.2
transgene was cloned from a human nkx2.2 cDNA clone
(Open Biosystems, Huntsville, AL). The enhanced green
ﬂuorescent protein (EGFP) plasmid (pLVTHM) and the
helper (pCMVDR8.91) and envelope (pMD2.G) plasmids
were kindly provided by Didier Trono (Ecole Polytech-
nique Fe ´de ´rale de Lausanne, Lausanne, Switzerland). The
vector constructs contained the Nkx2.2 sequence coupled
to EGFP via an IRES sequence or EGFP only as control.
Transcription was driven by the constitutively active
phosphoglycerate kinase (PGK) promoter. The vector also
contained a Simian vacuolating virus 40 (SV40)-driven
blasticidine-resistance gene for clonal selection.
The day before transduction, the target cells were pas-
saged onto six-well plates to reach a density of 60–80% on
the day of transduction (0.8–1 9 10
6 cells/well). For
transduction, the culture medium was removed, and new
medium containing freshly produced virus suspension was
added to cover the surface of the wells (750 ll/well). After
4 h incubation at 37C, 5% CO2, additional medium was
added (2 ml total), and the cells were incubated overnight.
The next day, the virus-containing medium was replaced
by fresh culture medium. Medium was changed every day.
Blasticidine (2 lg/ml) selection of transduced cells was
started 4 days after transduction. To analyze functionality
of the expression constructs, green ﬂuorescence as well as
Nkx2.2 expression of the transduced NSC was monitored
after selection in blasticidine for 6–10 days. Based on
EGFP expression, the transduction efﬁciency was 70 ± 5%
for the EGFP control virus and 65 ± 5% for the Nkx2.2/
EGFP virus.
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For RT-PCR, total RNA was extracted using the RNeasy
kit (Qiagen, Hilden, Germany), and cDNA was generated
using iScript (Bio-Rad, Mu ¨nchen). PCR was performed
using an iCycler (Bio-Rad) with SYBR Green detection.
For primers and conditions see Supplemental Materials and
Methods.
Results
Generation of cell-permeant Nkx2.2 protein
For TAT-mediated protein transduction, a fusion protein
composed of the TAT transduction domain and the Nkx2.2
protein was synthesized using a bacterial expression vector
[17]. The recombinant Nkx2.2 fusion protein is composed
of the transcription factor, a nuclear localization signal
(NLS), the TAT protein transduction domain (TAT-PTD)
and a histidine tag (Nkx2.2-NTH, Fig. 1a). The resulting
Nkx2.2 fusion protein (35 kDa) could be efﬁciently puri-
ﬁed by Ni-nitrilotriacetic acid chromatography from the
bacterial expression system as shown by Coomassie blue
staining as well as Western blot analysis using anti-5-his-
tidine and anti-Nkx2.2 antibodies (Fig. 1b–d). The stability
of the recombinant Nkx2.2-NTH protein in culture medium
and at 37C in the presence and absence of murine ESC-
derived NSC was conﬁrmed by Western blot analysis
(Fig. 1e). Nkx2.2 protein was detectable in medium up to
48 h both with and without cells. However, in the presence
of NSC the majority of the protein disappeared from the
medium after 48 h, suggesting protein internalization and/
or degradation. Efﬁcient protein transduction was con-
ﬁrmed by Western blot analysis of cell lysates from vehicle
(glycerol)- or Nkx2.2-NTH-treated NSC (Fig. 1f). Whereas
Nkx2.2 protein could not be detected in vehicle-treated
cells, a time-dependent uptake was observed following
Nkx2.2-NTH transduction. Intracellular protein degrada-
tion products could also be seen over time (arrows).
Cellular uptake of the recombinant protein was also visu-
alized by rhodamine labeling (Supplementary ﬁgure). Two
hours following transduction of ESC-derived NSC, the
labeled Nkx2.2 protein was localized in ‘endosome-like’
vesicles around the nucleus, suggesting protein uptake via
the endosomal pathway [7, 30].
Nkx2.2 protein transduction promotes oligodendrocyte
differentiation in differentiating NSC
We chose mouse ESC-derived NSC [42] for functional
validation of recombinant transducible Nkx2.2-NTH.
These cells exhibit endogenous expression of Olig2, Sox10
Fig. 1 Generation and puriﬁcation of recombinant Nkx2.2-NTH
protein. a Construction of the protein expression vector encoding the
human Nkx2.2 in fusion with sequences encoding a nuclear locali-
zation signal (NLS), the TAT transactivator protein transduction
domain to direct cellular uptake and a 6-histidine-tag (His) (Nkx2.2-
NTH). Expression and puriﬁcation of recombinant Nkx2.2 protein
from bacteria was demonstrated by Coomassie blue staining of a
SDS-PAGE (b) and Western Blot analysis using anti-Penta-His (c)
and anti-Nkx2.2 antibodies (d). e Stability of the recombinant protein
was analyzed under cell culture conditions in the presence and
absence of NSC. f Protein uptake was assessed by Western blot
analysis of cell lysates from vehicle (glycerol)- and Nkx2.2-NTH-
transduced NSC at the indicated time points. Internalized protein was
partly degraded over time (arrows). P pellet, SN supernatant, FT ﬂow-
through, W1 washing fraction 1, W2 washing fraction 2, E eluate, GS
glycerol stock
2442 K. Stock et al.and Sox9, whereas Nkx2.2 expression is largely absent
(Fig. 2b–e). The cells were grown on poly-L-ornithine/
laminin coated tissue culture dishes (150,000 cells/cm
2)
and proliferated in expansion medium containing FGF2
and EGF (Fig. 3a). Oligodendroglial differentiation was
induced by a 4-day growth factor withdrawal in the pres-
ence of T3 and ascorbic acid in differentiation medium
[43]. Nkx2.2-NTH was added daily during the last day of
proliferation in FGF2 and EGF and the subsequent 4-day
differentiation period (Fig. 3b). Control populations were
treated with glycerol buffer as vehicle only. Nkx2.2-NTH
protein transduction resulted in a twofold increase in the
number of oligodendrocytes expressing the O4 antigen as
determined by immunoﬂuorescence staining; 13.8 ± 1.8%
of Nkx2.2-transduced cultures expressed the oligodendro-
cyte-speciﬁc antigen (Fig. 3c, e), whereas control
populations only gave rise to 7.4 ± 0.6% O4-positive oli-
godendrocytes (Fig. 3d, e). In contrast, Nkx2.2
transduction yielded no signiﬁcant changes in the number
of cells expressing GFAP (43.0 ± 3.6%, control:
44.1 ± 2.5%) and bIII-tubulin (28.4 ± 8.1%, control:
32.3 ± 6.1%).
To study the dose dependency of Nkx2.2 transduction,
NSC were exposed to different concentrations of the
puriﬁed protein (2, 5, 10, 20 lg/ml). To exclude an
unspeciﬁc effect of protein transduction, cells were also
treated with a TAT-Cre fusion protein [24]. The number of
O4-positive oligodendrocytes peaked at 5 lg/ml and no
further increase in oligodendrocyte differentiation and
maturation was observed at higher concentrations (Fig. 3f).
In contrast, the same concentrations of Cre protein had no
effect on oligodendroglial differentiation compared to
vehicle-treated control populations (not shown).
To determine changes in the expression of neural marker
genes, total RNA was isolated after 1 day of proliferation
and a 4-day growth factor withdrawal-induced differenti-
ation from vehicle-treated control populations and cells
treated with Nkx2.2-NTH. Quantitative RT-PCR demon-
strated an increase in the expression of oligodendroglial
marker genes following Nkx2.2 protein transduction com-
pared to control cells (Fig. 3g). The early oligodendrocyte
markers Sox10 and NG2, but also genes typically expres-
sed in mature oligodendrocytes such as CNP, PLP and
MBP were upregulated in cells treated with the Nkx2.2
Fig. 2 Baseline expression of
gliogenic transcription factors in
ESC-derived NSC. a Schematic
representation of transcription
factors that determine the
neuron-glial switch and
oligodendrocyte speciﬁcation in
the developing neural tube
(adapted by permission from
Macmillan Publishers Ltd.
copyright 2004 [32]). b–e
Immunoﬂuorescence analysis
revealed expression of the
transcription factors Olig2,
Sox10 and Sox9 in proliferating
ESC-derived NSC. In contrast,
individual cells expressed low
levels of Nkx2.2. Scale bars
b–e 50 lm
Cell-permeant Nkx2.2 modulates NSC differentiation 2443protein. This was not the case for the astrocytic markers
GFAP and S100ß, which were even slightly decreased.
Together, our RT-PCR data conﬁrmed a promotion of
oligodendroglial differentiation following Nkx2.2 protein
transduction as observed in the immunocytochemical
studies.
Enhanced oligodendroglial differentiation was also
reﬂected by changes in morphology. Nkx2.2-transduced
cultures yielded more oligodendrocytes with a complex,
mature phenotype. Speciﬁcally, oligodendrocytes in
Nkx2.2-transduced cultures exhibited ramiﬁed multipolar
processes (Fig. 4a), whereas O4-positive cells in control
populations typically adopted a bipolar or poorly bran-
ched phenotype (Fig. 4b). In mature oligodendrocytes, the
main processes typically branch into secondary and ter-
tiary processes. To analyze the effect on maturation in
more detail, the ramiﬁcation of oligodendrocyte processes
was quantiﬁed. Nkx2.2-NTH protein transduction resulted
in more oligodendrocytes with a tertiary ramiﬁed pheno-
type, suggesting a shift from immature to more mature
Fig. 3 Nkx2.2 protein transduction promotes oligodendrocyte differ-
entiation in mouse ESC-derived NSC. Mouse ESC-derived NSC (a),
largely negative for endogenous Nkx2.2, were induced to differentiate
by growth factor withdrawal in the presence of T3 and ascorbic acid
(AA) and incubated with recombinant Nkx2.2 protein (5 lg/ml b).
c–e After 5 days transduced populations showed a twofold increase
of cells immunopositive for the oligodendrocyte-speciﬁc O4 antigen
(Nkx 2.2: 13.8 ± 1.8%, vehicle control: 7.4 ± 0.6%; mean ± SD).
***P\0.001 (Student’s t test). f Concentration-dependent effect of
Nkx2.2-NTH transduction on mouse ESC-derived NSC. A twofold
increase in the number of O4-positive oligodendrocytes (blue curve)
compared to vehicle-treated control cells (red dashed line) could be
detected already with 5 lg/ml protein. Higher concentrations had no
further effect on oligodendroglial differentiation (mean ± SD).
g Quantitative RT–PCR analysis of neural marker genes in differen-
tiated cultures of Nkx2.2-NTH-transduced NSC relative to control
populations. Nkx2.2 transduction resulted in an increase in transcripts
for early (sox10, ng2) and advanced (cnp, plp, mbp) oligodendroglial
differentiation, whereas astrocytic markers (gfap, s100ß) were slightly
decreased (mean ± SEM). DAPI was used for nuclear counterstain-
ing (blue). Scale bars a, c, d 50 lm
2444 K. Stock et al.oligodendrocytes. Using these criteria for morphological
maturity, 66.7 ± 3.1% of the oligodendrocytes in the
controls were immature, and 33.3 ± 3.1% showed a
mature phenotype. In contrast, Nkx2.2-NTH treatment
resulted in only 11.7 ± 3.8% immature and 88.3 ± 3.8%
mature oligodendrocytes (Fig. 4c). In addition, oligoden-
drocytes in Nkx2.2-transduced cultures but not control
populations exhibited prominent myelin-like membrane
sheet extensions (Fig. 4d). No differences in the total
number of cells immunopositive for the early oligoden-
drocyte marker NG2 could be observed between Nkx2.2-
treated and control populations (Nkx2.2 17.2 ± 4.9%,
control: 18.0 ± 4.0%; Fig. 4e, f). However, in Nkx2.2-
transduced populations many NG2-positive cells had
already initiated expression of O4 (Fig. 4e). In contrast,
the majority of NG2-positive cells in control cultures
displayed a bipolar phenotype of pre-oligodendrocytes
still negative for O4 expression (Fig. 4f). Speciﬁcally,
9.6 ± 2.2% of the Nkx2.2-transduced cells, but only
1.7 ± 1.5% of the control cells co-expressed NG2 and O4
(Fig. 4g).
Taken together, these data indicate that direct delivery
of the oligodendroglial transcription factor Nkx2.2 by
protein transduction promotes oligodendroglial maturation
in ESC-derived NSC cultures.
Differentiation effect of Nkx2.2 protein transduction
is comparable to lentiviral gene transfer
In order to evaluate how the non-genetic transduction of
Nkx2.2 compares to viral transduction in terms of efﬁ-
cacy, we also used lentiviral vectors to generate Nkx2.2-
overexpressing NSC and EGFP-expressing control cells
(Fig. 5a–c). Following virus transduction, ESC-derived
NSC were selected with blasticidine for at least 6–
10 days. Transgene expression was conﬁrmed by immu-
noﬂuorescence analysis of Nkx2.2 and EGFP expression.
The transgenic NSC were differentiated according to the
conditions used for protein transduction, i.e., proliferation
for 1 day in expansion medium containing FGF2 and EGF
and differentiation by growth factor withdrawal in the
presence of T3 and ascorbic acid for 4 days in differen-
tiation medium. Similar to Nkx2.2 protein transduction,
stable overexpression of Nkx2.2 resulted in a twofold
increase in oligodendrocytes expressing the O4 antigen in
differentiated cultures (Fig. 5d–g). While only
6.4 ± 1.2% of the cells infected with control virus
showed O4 immunoreactivity, 12.2 ± 2.1% of the NSC
stably overexpressing Nkx2.2 generated O4-positive oli-
godendrocytes. As observed after Nkx2.2-NTH protein
transduction, the Nkx2.2-overexpressing cultures con-
tained oligodendroglial cells with a more ramiﬁed, mature
phenotype compared to EGFP-expressing control cells as
shown by O4 and NG2 immunostaining (Fig. 5f, g). Thus,
with respect to promoting oligodendroglial differentiation
of ESC-derived NSC, Nkx2.2 protein transduction appears
to compete well with lentiviral transduction of this tran-
scription factor.
Fig. 4 Nkx2.2 protein transduction promotes oligodendrocyte mat-
uration in mouse ESC-derived NSC. a, b Immunoﬂuorescence
analysis of the O4 antigen reveals differences in morphological
maturation between Nkx2.2-transduced and control oligodendrocytes.
c Quantiﬁcation of oligodendrocyte maturation. Oligodendrocytes
with three or more branches were classiﬁed as mature. Nkx2.2-
transduced NSC generated more oligodendrocytes with a mature,
tertiary ramiﬁed phenotype compared to control cells. d Oligoden-
drocytes generated from Nkx2.2-transduced NSC formed myelin
sheath-like membrane protrusions (arrows). e, f Immunostaining for
the early oligodendroglial marker NG2 and O4 conﬁrmed the
differences in the developmental stages of oligodendrocytes in
Nkx2.2-transduced and control populations. g Quantitative analysis
of cells co-expressing NG2 and O4. The majority of NG2-positive
oligodendrocytes in the control population represented pre-oligoden-
drocytes, which could not be stained for the oligodendrocyte marker
O4. Shown are mean values ± SD. ***P\0.001 (Student’s t test).
DAPI was used for nuclear counterstaining (blue). Scale bars a, b, e,
f 25 lm, d 10 lm
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The results of this study show that direct transduction of the
gliogenic transcription factor Nkx2.2 as TAT fusion protein
promotesdifferentiationintoanoligodendrocyticphenotype
in differentiating ESC-derived NSC. Under cell culture
conditions, the puriﬁed fusion protein is stable for at least
24 h. When added to cultures of ESC-derived NSC, the
proteinwasefﬁcientlytakenupbythecellsasdeterminedby
Westernblotanalysisofcelllysatesanduptakestudiesusing
rhodamine-labeled protein. Moreover, the fusion protein
elicits a clear effect on the generation and maturation of
oligodendrocytes in differentiated cultures of ESC-derived
NSC. These cells were previously shown to exhibit tripo-
tential differentiation into neurons and glia with expression
of the oligodendrocyte-speciﬁc O4 antigen in up to 20% of
the cells under appropriate culture conditions, i.e., prolifer-
ation in FGF2, PDGF and Forskolin for 4 days to promote
the generation of oligodendrocyte progenitor cells followed
by growth factor withdrawal-induced terminal differentia-
tion [43]. However, for the current study NSC were directly
differentiated without the 4-day proliferation step in FGF2/
Fig. 5 Effects of Nkx2.2 protein transduction on oligodendrocyte
differentiation and maturation are comparable to lentiviral-mediated
gene transfer. a NSC derived from ESC were transduced with EGFP-
and Nkx2.2/EGFP-expressing lentiviruses (pPGK-IRES2-EGFP,
pPGK-Nkx2.2-IRES2-EGFP). Transgene expression in EGFP- (b)
and Nkx2.2/EGFP-transduced cells (c) was conﬁrmed by immuno-
ﬂuorescence analysis using anti-EGFP and anti-Nkx2.2 antibodies.
d Infected cells were selected with blasticidine (Bsd) for 6–10 days
before they were differentiated. Following a 4-day growth factor-
mediated differentiation in the presence of T3 and AA, cultures of
Nkx2.2-overexpressing cells contained more oligodendrocytes
positive for the O4 antigen (EGFP control: 6.4 ± 1.2%; Nkx2.2:
12.2 ± 2.1%; mean ± SD, ***P\0.001, Student’s t test). Oligo-
dendrocytes in cultures stably overexpressing Nkx2.2 also adopted a
more ramiﬁed mature phenotype compared to EGFP-expressing
control cells (f, g). NG2 immunostaining revealed the generation of
oligodendrocytes with complex ramiﬁed processes in Nkx2.2-trans-
duced cultures (f2), whereas control populations predominantly
exhibited NG2-positive pre-oligodendrocytes (g2). DAPI was used
for nuclear counterstaining (blue). Scale bars b, c 50 lm, f1, g1
50 lm, f2, g2 25 lm
2446 K. Stock et al.PDGF/Forskolin. Since these conditions usually generate
very low numbers of oligodendrocytes (\10%), we consid-
ered them particularly suitable for assessing a potential pro-
oligodendrogliogenic effect of the Nkx2.2-NTH fusion
protein in this proof-of-concept study. Indeed, following
protein transduction, the number of O4-positive oligoden-
drocytes observed after 4 days of in vitro differentiation of
ESC-derived NSC was doubled. Furthermore, oligoden-
drocytes emerging from Nkx2.2-NTH-treated cultures
showed a more mature phenotype with highly branched
processes and formation of myelin-like membrane sheet
extensions.Similarresultscouldbeobtainedbycomparative
studiesfollowingviralgenetransfer.Thesedataindicatethat
(1) direct intracellular delivery of transcription factors can
be used to modulate lineage differentiation in NSC cultures,
and (2) protein transduction is comparable to genetic mod-
iﬁcation in governing transcription factor-based biological
effects.However,withNkx2.2proteinorgenetransferESC-
derived NSCstillproducenotmorethan*20%O4-positive
oligodendrocytes, a number these cells were also able to
generate following propagation in FGF2/PDGF [43], sug-
gesting saturation at this point. Considering transcriptional
activation by growth factor-mediated signaling pathways,
similar mechanisms could be involved in both, the prolif-
eration step in FGF2/PDGF and Nkx2.2 expression.
In principle, the effect of Nkx2.2 protein transduction
could be due to a general shift in lineage differentiation
and/or an acceleration of oligodendrocyte maturation.
However, there is evidence that Nkx2.2 seems to be more
relevant at later stages for promoting oligodendrocyte
maturation, rather than for the speciﬁcation of oligoden-
drocyte progenitors [32]. Indeed, while Nkx2.2
transduction of ESC-derived NSC resulted in a twofold
increase in the number of O4-positive oligodendrocytes,
no differences in the number of NG2-positive early
pre-oligodendrocytes could be observed between Nkx2.2-
transduced and control populations. In addition, oligoden-
drocytes of Nkx2.2-transduced cultures exhibited a more
mature, ramiﬁed morphology and formed myelin-like
membrane sheet extensions. Results from quantitative PCR
analysis conﬁrmed an increase in the expression of myelin-
speciﬁc markers typically expressed in mature oligoden-
drocytes, such as CNP, PLP and MBP. Thus, our data
support the notion that Nkx2.2 protein transduction induces
oligodendrocyte maturation rather than a general change in
lineage commitment.
Protein transduction: an emerging tool for non-genetic
stem cell engineering
Forced expression of lineage speciﬁc transcription factors
has been shown to enhance induction of well-deﬁned
neural lineages in embryonic and adult stem cells [1–3,
37–41, 44]. However, the efﬁciency of DNA transfection
technologies is highly variable among different cell types
and can be low in primary cells, stem cells and tumor cells.
The utility of viral vectors is limited by DNA carrying
capacity, difﬁculty in reliable and cost-effective manufac-
turing and safety concerns such as random integration.
Other methods of delivering recombinant DNA into the
cell, such as lipofection and electroporation, suffer from
variable efﬁciency or severely compromise cellular via-
bility. In contrast, protein transduction allows the direct
delivery of proteins into mammalian cells both in vitro and
in vivo without genetic manipulation [6, 8, 14, 45, 46].
Speciﬁcally, protein transduction of transcription factors
could provide sufﬁcient stimulus for initiating a speciﬁc
cell fate while allowing a precise control of dose, onset and
length of expression. Noguchi et al. showed that recom-
binant pancreatic and duodenal homeobox transcription
factor-1 (PDX-1) protein can permeate pancreatic cells due
to an endogenous, antennapedia-like PTD and functions
similarly to endogenous PDX-1 by stimulating insulin gene
expression [47]. Similarly, TAT-PDX-1 protein transduced
into human ESC is able to induce insulin protein produc-
tion by activation of its downstream target genes [48]. In
addition to cell fate speciﬁcation, protein transduction
could also be used to maintain a certain multipotent pre-
cursor population by providing the required protein. In
such a way the recombinant form of the homeobox tran-
scription factor HOXB4 (TAT-HOXB4) was used to
proliferate hematopoietic stem cells in vitro, making it a
potential candidate for therapeutic stem cell expansion
[19]. Very recently, it has been shown that protein trans-
duction may also be used for delivering reprogramming
factors into somatic cells [17, 20, 21].
Here, we demonstrate that protein transduction is as
efﬁcient as virus-mediated gene transfer in transcription
factor-based promotion of NSC differentiation. Thus, pro-
tein transduction technology has the potential to become an
efﬁcient alternative to genetic modiﬁcation while allowing
temporal and reversible regulation of biological processes.
The results of our study show that 48 hafter application a
largefractionofthefusionproteincanstillbedetectedinthe
transduced cells (Fig. 1f). This time window should be
sufﬁciently broad to also permit simultaneous application of
several recombinant transcription factors, which cooperate
in cell fate determination. Alternatively, cell-permeant
transcription factors might be applied sequentially to mimic
successivetranscriptionfactorexpressioncascadesobserved
during normal development. Another advantage is that
individual cell-permeant proteins can be administered in a
titratable fashion as hasbeen demonstrated inprevious work
with TAT-Cre fusion proteins in both mouse and human
cells [24, 49]. Thus, protein transduction offers a series of
advantages, which cannot be easily achieved using
Cell-permeant Nkx2.2 modulates NSC differentiation 2447conventional gene-based methods. Considering that trans-
plantation of ESC derived oligodendrocytes has been
successfully applied for myelin repair in vivo [50, 51], the
approach presented here should also contribute to further
optimization of donor cell preparation for glial cell trans-
plantation. Beyond its use for modulating in vitro stem cell
differentiation, protein transduction might alsobe applied in
vivo. For example, in a recent study intravenous injection of
a TAT-Bcl-xL fusion protein has been shown to improve
survival of neuronal precursor cells in the lesioned striatum
after focal cerebral ischemia [52]. In conclusion, protein
transduction of recombinant transcription factors could
develop into an attractive tool to modulate differentiation
and promote survival of resident and cultured stem and
progenitor cells without genetic modiﬁcation.
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